Pharmacopeia Inc

Pharmacopeia — Pharmacopeia Drug Discovery — Investor Presentation (February 2007)

24 slides from Pharmacopeia's investor presentation, Feb 12, 2007

  1. Slide 1: Discovering excellence, driving clinical success

    Slide 1: Discovering excellence, driving clinical success

    Leslie J. Browne President & CEO New York City February 12th, 2007 Discovering excellence, driving clinical successTM

  2. Slide 2: Forward-Looking Statements

    Slide 2: Forward-Looking Statements

    Forward-Looking Statements . This presentation, and oral statements made with respect to information contained in this presentation, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those which e

  3. Slide 3: Value Drivers - Balanced Risk

    Slide 3: Value Drivers - Balanced Risk

    Value Drivers - Balanced Risk Biopharmaceutical company Focused on cardiovascular and immunological diseases Leader in developing DARA – Phase 1 dosing to start shortly First-in-class dual-acting ARB and endothelin antagonists for kidney disease Deep pipeline of potential blockbusters 6 compounds in

  4. Slide 4: Balancing Risk to Build Value

    Slide 4: Balancing Risk to Build Value

    Balancing Risk to Build Value 8 Million Compound Library Largest in the Industry Integrated HTS Medicinal Chemistry Pharmacology Development GSK Wyeth Organon Cephalon Bristol-Myers Squibb Unique Discovery Platform Strategic Partnerships Proprietary Programs High Value Portfolio Pharmacopeia Value D

  5. Slide 5: Agenda for Today

    Slide 5: Agenda for Today

    Agenda for Today Strong sustainable pipeline CXCR2 antagonist in Phase 2 for COPD p38 kinase inhibitors approaching Phase 2 DARA IND submitted December 28th, 2006 Strong strategic partnerships Wyeth R&D agreement on JAK3 GlaxoSmithKline R&D alliance Cephalon advanced discovery partnership Strong fun

  6. Slide 6: One of the Deepest Portfolios in Biotech

    Slide 6: One of the Deepest Portfolios in Biotech

    Metabolic Disease PS522501 Angiogenesis avb3/avb5 PS388023 Parkinsons Adenosine A2A PS246518 Rheumatoid/MS CCR1 PS375179 Derm/Ocular JAK3 Topical PS608504 Immuno/Inflam JAK3 PS608504 Inflammation PS873266 Respiratory PS948115 Inflammation PS386113 Oncology PS241541 CNS PS778629 Cardiovascular DARA P

  7. Slide 7: Partnered Pipeline Advancing

    Slide 7: Partnered Pipeline Advancing

    Partnered Pipeline Advancing Partnered clinical programs advancing CXCR2 antagonist for COPD In Phase 2 Active against biomarker at 50 mg in volunteers Clinical development on-going in COPD p38 kinase inhibitors for RA Approaching Phase 2 Well tolerated in multiple Phase 1 trials Currently in RA pat

  8. Slide 8: Agenda for Today

    Slide 8: Agenda for Today

    Agenda for Today Strong sustainable pipeline CXCR2 antagonist in Phase 2 for COPD p38 kinase inhibitors approaching Phase 2 DARA IND submitted December 28th, 2006 Strong strategic partnerships Wyeth R&D agreement on JAK3 GlaxoSmithKline R&D alliance Cephalon advanced discovery partnership Strong fun

  9. Slide 9: DARA – Dual Acting Angiotensin and Endothelin Receptor Antagonist

    Slide 9: DARA – Dual Acting Angiotensin and Endothelin Receptor Antagonist

    DARA – First-in-class DARA combines the properties of two marketed cardiovascular product classes in a single compound – Avapro and Tracleer Angiotensin II (Type 1) receptor blockers (ARBs) ETA selective endothelin receptor antagonists (ERAs) DARA’s combination of these activities has the potential

  10. Slide 10: ARB + ERA = Synergistic Combination

    Slide 10: ARB + ERA = Synergistic Combination

    ARB + ERA = Synergistic Combination Angiotensin II and Endothelin I Vasoconstriction Tissue proliferation and fibrosis Inflammation Preclinical Results - Resistant Hypertension Potent blockade of endothelin and angiotensin by oral route Potent BP lowering in two preclinical models predictive of acti

  11. Slide 11: PS433540 – Potent as ARB and ERA

    Slide 11: PS433540 – Potent as ARB and ERA

    PS433540 – Potent as ARB and ERA PS-433540 (DARA) 1.4 > 10,000 BMS-19384 > 10,000 2 Irbesartan (Avapro) Endothelin IC50 (nm, human) Angiotensin IC50 (nm, human) Compound Irbesartan(Avapro®) AT1 antagonist PS-433540 (DARA) AT1 and ETA antagonist BMS-193884 ETA antagonist Angiotensin group Endothelin

  12. Slide 12: Angiotensin and Endothelin Blockade in Vivo

    Slide 12: Angiotensin and Endothelin Blockade in Vivo

    Angiotensin and Endothelin Blockade in Vivo Angiotensin II PS433540 blocks both angiotensin and endothelin in vivo after oral administration in rodents with ED50 = 0.9, 7.6 mpk PS433540 Study PCO-NC-003 ED 50 = 0.9 mg/kg 0 10 20 30 40 50 60 70 80 90 100 Dose (mg/kg) 0.1 1.0 10.0 100.0 Vehicle-adjust

  13. Slide 13: PS433540 – Antihypertensive Activity

    Slide 13: PS433540 – Antihypertensive Activity

    PS433540 reduces blood pressure more than Irbesartan (Avapro) at 30 and 100 mmol/kg Effect of Irbesartan and PS433540 on Mean Arterial BP in Spontaneously Hypertensive Rats (SHR) PS433540 – Antihypertensive Activity

  14. Slide 14: New Treatment Options

    Slide 14: New Treatment Options

    New Treatment Options Demonstration of antihypertensive effect of PS433540 would support potential benefits in diabetic kidney disease Opportunity for DARA to be an attractive option in resistant hypertension and kidney disease Combine ARB and ERA activity in a single compound, once-a-day pill Avoid

  15. Slide 15: DARA Development Schedule

    Slide 15: DARA Development Schedule

    DARA Development Schedule Complete data and material transfer from BMS 2Q-06 Synthesis of 2 Kg GMP of active ingredient (API) 3Q-06 Pre-IND meeting with FDA 08/15/06 3Q-06 Submit IND 12/28/06 1Q-07 ‘First in man’ dosing 1Q-07 Complete AII challenge study Mid-07 Complete multiple ascending dose study

  16. Slide 16: Early Clinical Evaluation Phase

    Slide 16: Early Clinical Evaluation Phase

    Early Clinical Evaluation Phase 1 Safety and Pharmacology in Healthy Subjects Establish Safety SAD (Single Ascending Dose) – up to 7 dose levels MAD (Multiple Ascending Dose) – up to 4 dose levels Confirm Dual Activity Mechanism Angiotensin Challenge in Healthy Volunteers Endothelin Challenge in Hea

  17. Slide 17: Agenda for Today

    Slide 17: Agenda for Today

    Agenda for Today Strong sustainable pipeline CXCR2 antagonist in Phase 2 for COPD p38 kinase inhibitors approaching Phase 2 DARA IND submitted December 28th, 2006 Strong strategic partnerships Wyeth R&D agreement on JAK3 GlaxoSmithKline R&D alliance Cephalon advanced discovery partnership Strong fun

  18. Slide 18: Strategic Partnerships

    Slide 18: Strategic Partnerships

    Strategic Partnerships Pharmacopeia prosecutes Phase 1 and Phase 2 Non-dilutive tranched funding - $15 million Up to $83 million per program in milestones Double-digit royalties Builds portfolio and clinical infrastructure Late stage optimization programs Upfront $15 million technology access fee Up

  19. Slide 19: Strategic Partnerships

    Slide 19: Strategic Partnerships

    Strategic Partnerships Alliance to develop and commercialize JAK3 Inhibitors for Immunological and Inflammatory Diseases Upfront payment for discovery phase program - $5 million Up to $9MM in research funding over 3 years Up to $175MM in preclinical, clinical and commercialization milestones Double-

  20. Slide 20: Agenda for Today

    Slide 20: Agenda for Today

    Agenda for Today Strong sustainable pipeline CXCR2 antagonist in Phase 2 for COPD p38 kinase inhibitors approaching Phase 2 DARA dosing expected to start in Phase 1 shortly Strong strategic partnerships Wyeth R&D agreement on JAK3 GlaxoSmithKline R&D alliance Cephalon advanced discovery partnership

  21. Slide 21: Financial Summary

    Slide 21: Financial Summary

    Financial Summary For the 9-Months Ended September 30, 2006 $13.7 million in net revenue $19.6 million in net loss (including $2.0 million non-cash charge) Cash, Cash Equivalents and Marketable Securities $30.4 million as of December 31, 2005 $31.0 million as of September 30, 2006 Received $20 milli

  22. Slide 22: Stock Information

    Slide 22: Stock Information

    Stock Information Stock Exchange: NASDAQ Stock Symbol: PCOP Shares Outstanding (10/31/2006): 21.1 million 52- Week Range: $3.56 - $6.51 Market Capitalization (02/08/2007): ~ $95 million Enterprise Value*: ~ $40 million *Calculated on cash and liquid investments as of 09/30/2006 and financing proceed

  23. Slide 23: Pharmacopeia Today

    Slide 23: Pharmacopeia Today

    Pharmacopeia Today DARA Phase 1 clinical development First-in-class approach to significant markets Resistant Hypertension Diabetic Nephropathy Dosing in Phase 1 planned to start shortly Partnered clinical programs advancing CXCR2 antagonist in Phase 2 for COPD (partnered with Schering-Plough) p38 k

  24. Slide 24: Discovering excellence, driving clinical success

    Slide 24: Discovering excellence, driving clinical success

    Discovering excellence, driving clinical successTM

Source: SEC EDGAR · 8-K filed Feb 12, 2007

More decks from Pharmacopeia Inc